AR070158A1 - Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa - Google Patents
Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappaInfo
- Publication number
- AR070158A1 AR070158A1 ARP090100098A ARP090100098A AR070158A1 AR 070158 A1 AR070158 A1 AR 070158A1 AR P090100098 A ARP090100098 A AR P090100098A AR P090100098 A ARP090100098 A AR P090100098A AR 070158 A1 AR070158 A1 AR 070158A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacture
- pharmaceutical composition
- kappa
- rceptors
- benzamida
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380012 | 2008-01-22 | ||
| US3912108P | 2008-03-25 | 2008-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070158A1 true AR070158A1 (es) | 2010-03-17 |
Family
ID=40876972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100098A AR070158A1 (es) | 2008-01-22 | 2009-01-13 | Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa |
Country Status (32)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017484B1 (ru) * | 2008-01-22 | 2012-12-28 | Эли Лилли Энд Компани | Селективный антагонист опиоидных рецепторов каппа |
| NZ587215A (en) * | 2008-01-22 | 2012-08-31 | Takeda Pharmaceutical | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them |
| WO2013040321A1 (en) * | 2011-09-15 | 2013-03-21 | University Of Kansas | Kappa opioid receptor effectors and uses thereof |
| WO2013042054A1 (en) | 2011-09-19 | 2013-03-28 | Carmel - Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| CA2858752C (en) | 2011-12-09 | 2019-12-31 | Research Triangle Institute | 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| WO2014190270A1 (en) * | 2013-05-24 | 2014-11-27 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| JP7132237B2 (ja) | 2017-03-17 | 2022-09-06 | ザ スクリプス リサーチ インスティテュート | κオピオイド受容体アンタゴニストならびにそれに関連する産物および方法 |
| JP6480616B1 (ja) | 2018-02-08 | 2019-03-13 | 有限会社 ディオン光学技研 | 照準スコープ |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| CN114591211B (zh) * | 2020-12-04 | 2025-10-21 | 广东东阳光药业股份有限公司 | 一种酰胺化合物的共晶及其制备方法 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| KR20240004857A (ko) | 2021-05-04 | 2024-01-11 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 조성물 및 방법 |
| CN118843459A (zh) * | 2022-01-10 | 2024-10-25 | 杨森制药公司 | 用于治疗抑郁症的组合物和方法 |
| MX2024008618A (es) * | 2022-01-10 | 2024-09-25 | Janssen Pharmaceuticals Inc | Composiciones y métodos para el tratamiento de la depresión. |
| TW202400135A (zh) * | 2022-03-07 | 2024-01-01 | 美商健生醫藥公司 | 包含阿替卡普蘭之組成物 |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| CN119156210A (zh) * | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 纯形式的结晶阿替卡普兰 |
| JP7176142B1 (ja) | 2022-03-09 | 2022-11-21 | 直迪 清瀬 | 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| CA2372040C (en) * | 1999-05-12 | 2008-12-02 | Francois Jenck | Imidazodiazepine derivative |
| WO2002029418A1 (en) * | 2000-10-05 | 2002-04-11 | Hanns Mohler | Selective anxiolytic therapeutic agents |
| US6528518B2 (en) | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| BR0308918A (pt) * | 2002-03-28 | 2005-01-04 | Wisys Technology Found Inc | Agentes ansiolìticos com efeitos sedativos e atáxicos reduzidos |
| MY140236A (en) | 2002-09-19 | 2009-12-31 | Lilly Co Eli | Diarylether compounds useful as opioid receptor antagonists |
| BRPI0407616A (pt) | 2003-03-07 | 2006-02-14 | Lilly Co Eli | composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste" |
| ATE406360T1 (de) | 2003-03-07 | 2008-09-15 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| US7196100B2 (en) | 2003-12-12 | 2007-03-27 | Eli Lilly And Company | Opioid receptor antagonists |
| AU2004312312A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2005089745A1 (en) | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| CA2558568A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
| JP2007528898A (ja) | 2004-03-12 | 2007-10-18 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
| WO2005092836A1 (en) | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
| DE602005012380D1 (de) | 2004-03-15 | 2009-03-05 | Lilly Co Eli | 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit |
| WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| DE502007002185D1 (de) | 2006-04-04 | 2010-01-14 | Emodys Gmbh | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
| JP2010500372A (ja) | 2006-08-09 | 2010-01-07 | スミスクライン ビーチャム コーポレーション | オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物 |
| CN101522614B (zh) | 2006-08-09 | 2014-06-25 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的化合物 |
| CA2662766C (en) | 2006-09-08 | 2011-08-09 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
| EA017484B1 (ru) * | 2008-01-22 | 2012-12-28 | Эли Лилли Энд Компани | Селективный антагонист опиоидных рецепторов каппа |
-
2009
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en not_active Ceased
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active Active
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
-
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
-
2012
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6290644A2 (es) | Antagonista del receptor opioide selectivo kappa. | |
| PE20121820A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella | |
| CO6321265A2 (es) | Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso | |
| BR112015014222A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica | |
| UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| CL2009000815A1 (es) | Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria. | |
| CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
| ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| PE20140099A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| CR20150114A (es) | Composición farmacéutica recubierta que contiene regorafenib | |
| CL2013003597A1 (es) | Compuestos derivados de n-[4-(2-oxo-1,2-dihidropiridin-4-il)bencil]benzamida; composicion farmaceutica y su uso para tratar la dependencia quimica a un agente productor de dopamina como cocaina, opiaceos, anfetaminas, nicotina y alcohol y para tratar la obesidad. | |
| CL2008003789A1 (es) | Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer. | |
| MA37886B1 (fr) | Nouvelles pyridinones bicycliques | |
| CL2010000059A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer. | |
| AR078951A1 (es) | Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| ECSP22032016A (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. | |
| AR079343A1 (es) | Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico | |
| AR114930A1 (es) | Composición farmacéutica | |
| BR112012006233B8 (pt) | composto de fórmula i, composição farmacêutica e usos de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |